Login to Your Account



Ascentage nabs $72M series B round, preps for U.S. public listing

By Shannon Ellis
Staff Writer

Tuesday, January 3, 2017

SHANGHAI – Small-molecule oncology drug developer, Ascentage Pharma Group, of Taizhou, Zhejiang, has raised ¥500 million from Future Industry Investment Fund.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription